Did Oxford Biomedica just find a new treatment for Parkinson’s disease?

Zaven Boyrazian takes another look at Oxford Biomedica after promising results on its Parkinson’s disease treatment were announced.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I have previously written about Oxford Biomedica (LSE:OXB) and its attempt to become a leader in a $14bn industry. Today it announced an update on one of its partnerships with Axovant Gene Therapies — specifically a new treatment for Parkinson’s disease.

As a reminder, Oxford Biomedica is a gene and cell therapy biotechnology company. Using its proprietary LentiVector platform, the firm collaborates with large pharmaceutical companies — such as Bristol Myers Squibb and Novartis. It helps them develop new drugs that would otherwise be too expensive or technically challenging to pursue. The company charges for its bio-processing services during drug development and continues to receive royalties after approval.

Today the company announced a progress update on the development on AXO-Lenti-PD – a gene therapy programme for Parkinson’s disease. This treatment is one of 18 products using the LentiVector Platform and is now transitioning into stage two trials.

A new potential Parkinson’s disease treatment?

The announcement was mixed with both good and bad news.

The good news is that initial testing has shown the drug to be working. Patient-level data in the second cohort demonstrated consistent treatment outcomes providing evidence of dose-response. Patients saw an increase in ‘On’ time and a decrease in ‘Off’ time as compared to their original baseline.

Put simply, the patient’s ability to retain control over their body movements improved significantly, with no adverse side effects of the gene therapy. This brings the whole world one step closer to a new and improved treatment for Parkinson’s disease. However, it is essential to remember that there is a long way to go before it can become an approved medicine.

Furthermore, the bad news portion of the announcement extends this waiting period further.

Due to delays in chemistry, manufacturing & controls (CMC) data and third-party packaging – likely attributable to disruptions caused by Covid-19 – the continued development of this treatment is going to take longer than expected.

As a result, the next planned stage of a randomized sham-controlled trial for AXO-Lenti-PD will not enroll new patients before the end of 2021. Currently, it is unclear how long the delay will be. However, Axovant has stated an update will be issued in Q1 2021 once the development timelines have been clarified.

The bottom line

These delays in manufacturing are naturally going to prolong the development cycle for this particular treatment. However, the cause of these delays are short-term problems and unlikely to become a recurring issue.

There has so far been no impact on other products in development. Therefore, I think investors have no need to worry. However, if future announcements of delays begin to emerge, it may be a sign of an underlying problem in the business that its competitors may take advantage of.

With a promising set of results and only a temporary setback for the company, I still believe Oxford Biomedica is an outstanding growth stock on track to becoming a leader within its industry.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian owns shares in Oxford Biomedica. Zaven Boyrazian’s mother works for Bristol Myers Squibb. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »